Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

Robert W. Veltri, M. Craig Miller, Gang Zhao, Angela Ng, Garry M. Marley, George L. Wright, Robert L. Vessella, David Ralph

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives. Using arbitrarily primed polymerase chain reaction (AP-PCR) ribonucleic acid (RNA) fingerprinting, we discovered a messenger RNA (mRNA) that encoded the cytokine interleukin-8 (IL-8) that was up-regulated in the peripheral blood leukocytes (PBLs) of patients with metastatic prostate cancer (CAP) compared with similar cells from healthy individuals. We compared the total prostate-specific antigen (PSA) levels, the free/total (f/t) PSA ratios, and the immunoreactive IL-8 serum concentrations in patients with either biopsy-confirmed benign prostatic hyperplasia (BPH) or CaP. Methods. The sera from 35 apparently healthy normal volunteers and 146 patients with biopsy-confirmed BPH and CaP obtained from two academic centers were retrospectively examined to determine the serum levels of IL-8, total PSA (tPSA), and the f/t PSA ratio. Logistic regression and trend analysis statistical methods were used to assess the results. Results. Normals (n = 35), BPH patients (n = 53), patients with clinical Stages A to C CaP (n = 81), and patients with metastatic CaP (n = 12) had mean levels of IL-8 of 6.8, 6.5, 15.6, and 27.8 pg/mL, respectively. The IL-8 serum concentrations correlated with increasing CaP stage and also differentiated BPH from clinical Stages A, B, C, or D CaP better than tPSA and performed similarly to the f/t PSA ratio. The combination of the IL-8 levels and f/t PSA ratios using multivariate logistic regression analysis distinguished BPH from Stages A, B, C, or D CaP or only Stages A and B with a receiver operating characteristic area under the curve of 89.8% and 87.5%, respectively (P <0.0001). Conclusions. The IL-8 serum concentration in our clinically well- defined patient sample was independent of the f/t PSA ratio as a predictor of CaP. When test samples are controlled for extraneous clinical origin of inflammation or infection, the combination of the IL-8 and f/t PSA assay results may offer an improved approach for distinguishing BPH from CaP.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalUrology
Volume53
Issue number1
DOIs
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer'. Together they form a unique fingerprint.

Cite this